Q4 2025 Verrica Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Verrica Pharmaceuticals Inc (VRCA) achieved a 130% increase in YCANTH revenue compared to 2024, while reducing selling, general, and administrative expenses by over 40%.
- The company received $18 million in milestone payments from its Japanese partner, Torii Pharmaceutical, and executed a $50 million equity raise, strengthening its financial position.
- Verrica Pharmaceuticals Inc (VRCA) launched a global Phase 3 program for YCANTH for common warts, with Torii funding the first $40 million of clinical trial costs.
- The company reported a 368% year-over-year growth in total revenue for 2025, reaching $35.6 million.
- Verrica Pharmaceuticals Inc (VRCA) extended its cash runway into 2027 and eliminated all outstanding debt, providing financial stability for future operations.
- YCANTH dispensed applicator units decreased by approximately 3% from the third quarter to the fourth quarter of 2025.
- The company experienced a sequential decline in applicator sales, attributed to gaps in the sales force that were being backfilled.
- Verrica Pharmaceuticals Inc (VRCA) reported a GAAP net loss of $8.1 million for the fourth quarter of 2025, although this was an improvement from the previous year.
- The company has not yet disclosed the full development program and timing for the VP-315 Phase 3 program, creating uncertainty about future costs.
- Verrica Pharmaceuticals Inc (VRCA) faces competition from other treatments for molluscum contagiosum, such as Zelsuvmi, which could impact market share.
Good morning, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals fourth quarter and year-end 2025 corporate update conference call. (Operator Instructions) As a reminder, this conference is being recorded.
I will now turn the call over to our host, Kevin Gardner of LifeSci Advisors. You may begin your conference.
Thank you, operator. Hello, everyone, and welcome to Verrica Pharmaceuticals fourth quarter and year-end 2025 corporate update conference call. With me on the line this morning are Jayson Rieger, President and Chief Executive Officer; Noah Rosenberg, Chief Medical Officer; John Kirby, Interim Chief Financial Officer; David Zawitz, Chief Operating Officer; and Chris Chapman, Chief Commercial Officer.
As a reminder, during today's call, management will make forward-looking statements. These forward-looking statements are based on the company's current expectations and involve inherent risks and uncertainties. Verrica's actual results and the timing of events could differ materially from those anticipated in such
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
